The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo-Reference-Cited by-同舟云学术

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Published:2013-07-09 Issue:10 Volume:27 Page:2086-2091
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Todisco E,Ciceri F,Oldani E,Boschini C,Micò C,VanLint M T,Donnini I,Patriarca F,Alessandrino P E,Bonifazi F,Arcese W,Barberi W,Marenco P,Terruzzi E,Cortelazzo S,Santarone S,Proia A,Corradini P,Tagliaferri E,Falcioni S,Irrera G,Dallanegra L,Castagna L,Santoro A,Camboni A,Sacchi N,Bosi A,Bacigalupo A,Rambaldi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013208.pdf

Reference13 articles.

1. Greinix HT, Reiter E, Keil F, Fischer G, Lechner K, Dieckmann K et al. Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. Bone Marrow Transplant 1998; 21: 673–678.

2. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157–1163.

3. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108–114.

4. Estey E . Treatment of refractory AML. Leukemia 1996; 10: 932–936.

5. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808–813.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML;Cancers;2024-08-16

2. CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia;Annals of Hematology;2023-10-17

3. Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years;European Journal of Haematology;2022-10

5. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis;Clinical Cancer Research;2022-06-07